Clusterin expression is associated with decreased disease-free survival of patients with colorectal carcinomas

Histopathology

Volumn 56, Issue 7, 2010, Pages 932-936

  Redondo, Maximino ^a   Rodrigo, Isabel ^b   Alcaide, Julia ^b   Tellez, Teresa ^a   Roldan, María J ^a   Funez, Rafael ^b   Diaz Martin, Aurelio ^b   Rueda, Antonio ^b   Jiménez, Eugenio ^c  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b HOSPITAL COSTA DEL SOL   (Spain)

^c UNIVERSIDAD DE MÁLAGA   (Spain)

Author keywords

Clusterin; Colorectal carcinomas; Prognosis

Indexed keywords

CLUSTERIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; COLON CARCINOGENESIS; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CYTOPLASM; DISEASE FREE SURVIVAL; EPITHELIUM CELL; FEMALE; GENDER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; ADENOMA; CARCINOMA; COLORECTAL TUMOR; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADENOMA; AGED; AGED, 80 AND OVER; CARCINOMA; CLUSTERIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; KAPLAN-MEIER ESTIMATE;

EID: 77953210382     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03565.x     Document Type: Article

References (25)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence world-wide, 10th edn.
2. Trougakos IP, Gonos ES. Clusterinapolipoprotein J in human aging and cancer. Int. J. Biochem. Cell Biol. 2002 34 1430 1448.
3. Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J. Biol. Chem. 2003 278 11590 11600.
4. Pucci S, Bonnanno E, Pichiorri F, Angeloni C, Spagnoli LG. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 2004 23 2298 2304.
5. Miyake H, Nelson C, Rennie PS, Gleave ME. Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res. 2000 60 170 176. (Pubitemid 30058748)
6. Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES. Silencing expression of the clusterinapolipoprotein j gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. Cancer Res. 2004 64 1834 1842.
7. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY. Clusterin inhibits apoptosis by interacting with activated Bax. Nat. Cell Biol. 2005 7 909 915.
8. Gleave M, Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J. Urol. 2005 23 38 46.
9. Redondo M, Téllez T, Roldan MJ et al. Anticlusterin treatment of breast cancer cells increases chemotherapy- and tamoxifen-sensitivity and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity. Breast Cancer Res. 2007 9 R86.
10. Kurahashi T, Muramaki M, Yamanaka K, Hara I, Miyake H. Expression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extension. BJU Int. 2005 96 895 899.
11. Kang YK, Hong SW, Lee H, Kim WH. Overexpression of clusterin in human hepatocellular carcinoma. Hum. Pathol. 2004 35 1340 1346.
12. Krüger S, Mahnken A, Kausch I, Feller AC. Value of clusterin immunoreactivity as a predictive factor in muscle-invasive urothelial bladder carcinoma. Urology 2006 67 105 109.
13. Miyake H, Yamanaka K, Muramaki M, Kurahashi T, Gleave M, Hara I. Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. Oncol. Rep. 2005 14 1371 1375.
14. Krüger S, Ola V, Fischer D, Feller AC, Friedrich M. Prognostic significance of clusterin immunoreactivity in breast cancer. Neoplasma 2007 54 46 50.
15. Zhang S, Zhang D, Zhu Y, Guo H, Zhao X, Sun B. Clusterin expression and univariate analysis of overall survival in human breast cancer. Technol. Cancer Res. Treat. 2006 5 573 578.
16. Redondo M, Villar E, Torres-Muñoz J, Tellez T, Morell M, Petito CK. Overexpression of clusterin in human breast carcinoma. Am. J. Pathol. 2000 157 393 399.
17. Xie MJ, Motoo Y, Su SB et al. Expression of clusterin in human pancreatic cancer. Pancreas 2002 25 234 238.
18. Albert JM, Gonzalez A, Massion PP et al. Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol. Biomarkers Prev. 2007 16 1845 1851.
19. Chen X, Halberg RB, Ehrhardt WM, Torrealba J, Dove WF. Clusterin as a biomarker in murine and human intestinal neoplasia. Proc. Natl Acad. Sci. USA 2003 100 9530 9535.
20. Kevans D, Foley J, Tenniswood M et al. High clusterin expression correlates with a poor outcome in stage II colorectal cancers. Cancer Epidemiol. Biomarkers Prev. 2008 18 393 399.
21. Andersen CL, Schepeler T, Thorsen K et al. Clusterin expression in normal mucosa and colorectal cancer. Mol. Cell Proteomics 2007 6 1039 1048.
22. Sensibar JA, Sutkowski DM, Raffo A et al. Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin). Cancer Res. 1995 55 2431 2437.
23. Steinberg J, Oyasu R, Lang S et al. Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. Clin. Cancer Res. 1997 3 1707 1711.
24. Xie D, Sham JS, Zeng WF et al. Oncogenic role of clusterin overexpression in multistage colorectal tumorigenesis and progression. World J. Gastroenterol. 2005 11 3285 3289.
25. Redondo M, Esteban F, González-Moles MA et al. Expression of the antiapoptotic proteins clusterin and bcl-2 in laryngeal squamous cell carcinomas. Tumour Biol. 2006 27 195 200.